about
Cyclooxygenase-2 as a target for anticancer drug developmentEfficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II studySunitinib versus interferon alfa in metastatic renal-cell carcinomaA risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignanciesA Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid MalignanciesThe indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.Metastatic melanoma: chemotherapy.Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors.Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activationLung cancer in patients with HIV Infection and review of the literature.High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.Proteasome inhibition: a new approach for the treatment of malignancies.Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?Validation of analytic methods for biomarkers used in drug developmentRenal toxicity of targeted therapies.Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.Axitinib (AG-013736).Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity.Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice.Sunitinib malate.Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study.A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.Renal cell carcinoma: ten years of significant advances.Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!Biochemotherapy for advanced melanoma: maybe it is real.Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study.Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model.Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.[Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)].
P50
Q28195645-AA506678-6600-42E3-ABAF-BD94889BF642Q28282189-5A97456B-8DD1-4E6A-897F-55585EB4B5A2Q28282757-44EEAAFE-8A40-4CB2-BBBC-68B956D52BBAQ33410742-BEE78E74-FCD6-4414-92BC-519DF9A5D4E6Q33423203-69685F12-A7AE-405D-AFD8-9FCBF47E3A10Q33735754-267FE2E5-4DFC-4D02-820B-4483ADE20DACQ33929529-EFFCD475-F07B-4112-865C-E1D61E7DBACAQ34156931-04B8164A-47FD-4E6F-BD73-7C0125073902Q34245458-8B7F3F89-03FD-4483-9CDC-6ED190664AC9Q34334516-488B8831-8A66-4532-84F5-2A66888A8F71Q34584163-E162EC04-89E7-43AB-B370-06A9539AFED9Q35221471-7B39BC70-1C01-48FD-940A-F677D90B199CQ35858070-B77B7218-F92C-468F-A032-FACF78D26BC2Q36117735-B8390004-DE82-4CC6-AC4F-0EE592FBDA71Q36326490-6EC71218-65F6-435B-BA30-07D421F98972Q36894975-8413C46B-FB8C-4BD7-A98A-8A13F1B5E147Q37038239-90CEF217-533A-4ECF-83AD-84B1471F82B9Q37284255-B2D2C69E-3D03-4F9A-9549-CD48D372C08CQ37473177-238093E8-04D5-4308-A130-B7514D82993BQ37624473-99D2F5AD-08AE-422A-915E-560177FA4B92Q37639225-9CF8AA2D-D5B9-4B3D-B696-60E2EAC1B47AQ37674170-6079AEB7-6BFA-460C-BED5-017ADB9CA359Q37816164-D4CEF3C2-AD8E-4E03-A7AF-3FA681573B1BQ38514440-424F2DD5-4492-4C13-B83D-1F24D35AE8C0Q39398750-65B314B9-6397-485E-9C33-C6C5AF2017A7Q40202597-F7416A79-0653-49F9-B823-9F118501104DQ40510197-22350CFA-C7DA-4D6F-9A05-2CFBBE19B98CQ41129245-D24CA23E-E550-4A62-A72C-806EF187D889Q41496075-C602BBDA-CCA6-44C4-B4AD-D75710B0E565Q42627893-3518788D-5A6A-4431-A090-FDF738273567Q42939988-2248F9C0-2AF7-4653-A547-507A3DD586CFQ42995703-EAC2F37B-DC47-4E04-AADA-E09B3411735EQ43181709-138C9957-36EB-4FBE-A0A3-0C3A4009966AQ43918759-C0A42087-EB4A-41BD-8E7A-643A10ABB522Q43993862-CF219028-D01C-47C6-87CC-12802F1A1EEDQ44200284-2FD88D0D-A607-4567-AE0C-6521B968B8E8Q44683203-3C4649C1-9D6F-4778-9B45-AB03967483DCQ44943010-58E9476F-404C-41AA-89B0-0E29E1BD2862Q45011636-0269E0A6-B9C8-466E-BF74-3F6E3291A478Q45069493-2552D43E-6CF7-4906-8B4F-9F474123F040
P50
name
Olivier Rixe
@en
Olivier Rixe
@nl
type
label
Olivier Rixe
@en
Olivier Rixe
@nl
prefLabel
Olivier Rixe
@en
Olivier Rixe
@nl